Abstract: The present invention relates to a method for treating and a method for identifying a tumor of a human or animal comprising administering composition comprising an agent which binds to Frizzled 9.

Abstract: The invention relates to a monoclonal antibody, or fragments thereof, for isolating and/or identifying mesenchymal stem cells. In this connection, the antibody, or fragments thereof, bind to an antigen which is the same as that bound to by an antibody which is produced by the hybridoma cell line W8B2, which was deposited on 14.08.2002 in the DSMZ [German collection of microorganisms and cell cultures] under the number DSM ACC2567.

Abstract: An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region.

Abstract: The present invention relates to a therapeutic or/and diagnostic substance. Furthermore it relates to an expression vector, to a composition comprising the afore-mentioned substance or/and the afore-mentioned expression vector, a method for diagnosing a tumor disease or/and an infectious disease in a living being, as well as to a method for the treatment of a tumor disease or/and of an infection in a living being.

Abstract: The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liabilty for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceut

Abstract: A method and a device are used for determining a characteristic value for the perfusion of modified, in particular pigmented tissue regions in organs of living beings, for example the skin. By means of a laser flowmeter, a first volumetric flow rate and a second volumetric flow rate of the blood are determined at a first measurement point and at a second measurement point, respectively within the modified tissue region and within the surrounding, unmodified tissue region, in each case as a measurement profile of a volumetric flow rate signal as a function of time. A wavelet analysis of each of the measurement profiles is then carried out as a three-dimensional representation of the signal intensity over a frequency or scaling axis and time.

Abstract: The present invention relates to mono clonal antibodies or fragments thereof for isolating and/or identifying neural progenitor cells. The antibodies or fragments thereof bind to an identical antigen as an antibody which is produced by the hybridoma cell lines W4A5, W8C3 and 57D2 deposited on Aug. 14, 2002, at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) under the numbers DSM ACC2571, DSM ACC2570 and DSM ACC2568.

Abstract: A method for treating viral diseases which are caused by DNA viruses is described comprising administering an effective amount of at least one inhibitor of reverse transcriptase (RTI) in combination with at least one inhibitor of viral DNA polymerase, wherein the at least one RTI and the at least one DNA polymerase inhibitor are present in the form of separate compounds.

Abstract: The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liability for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceu

Abstract: Devices having at least one surface which comes into contact with tissues and/or fluids of the human or animal body. These surfaces are at least partially coated with aptamers, which mediate the adhesion of biological material.

Abstract: The present invention relates to an antibody for the detection quantification, or isolation of basophils, mast cells, the precursor cells of basophils or mast cells, or a surface structure of basophils or mast cells. This antibody corresponds to an antibody with the designation 97A6, produced and released by hybridoma cells that were deposited in accordance with the Budapest Treaty on Feb. 12, 1997 under accession number DSM ACC 2297 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ).

Abstract: An operation kit is provided for access into the subretinal region of the eye. The kit comprises an elongated flat body of soft material, which can be inserted into the subretinal region from the side through an incision in the sclera. The body is formed as a strip, whose one surface is configured as a guiding surface for a medical device, for example for implanting a microphotodiode chip.

Abstract: The invention makes available a peptide having a radioprotective effect that comprises a modified form and/or an optionally modified fragment of the Bowman-Birk protease inhibitor (BBI).

Abstract: For the detection of fungal cells in clinical material fungal DNA is extracted from whole blood and the extracted fungal DNA is then detected. From this detection, a fungal infection can be concluded. For further diagnosis, the fungal species are then determined from the extracted fungal DNA. The method for extraction of the fungal DNA from whole blood comprises the isolation of predominantly intact fungal cells from the whole blood and the extraction of DNA from the isolated fungal cells. For detection of fungal DNA, at least one segment of the fungal DNA to be detected is amplified, then the amplification products are detected. For further identification of the fungal species, nucleotide sequence segments being characteristic for the fungal species are detected.